Key metrics included time in the target glucose range (3–10 mmol/L), percentage of time spent in hypoglycemia (<3 mmol/L), and hyperglycemia (>10 mmol/L), alongside insulin dosage requirements. This evidence concerns the gene INS and Hyperglycemia.